Patent · US Active

Soluble and immunoreactive Zika virus NS1 polypeptides comprising the wing domain

US11312750B2 · kind B2 · utility

1Cited by

0References

9Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Elke Faatz · Huglfing, DE
Mario Gloeck · Geretsried, DE
Peter Muench · Penzberg, DE
Alexander Riedel · Munich, DE
Christian Scholz · Penzberg, DE
Gloria Tabares · Penzberg, DE

Key dates

Filing date	Oct 25, 2019
Grant date	Apr 26, 2022
Priority date	—
Expiry date	Jan 16, 2040

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure concerns a polypeptide suitable for detecting antibodies against Zika virus in an isolated biological sample having a Zika virus NS1 wing domain specific amino acid sequence and variants thereof, wherein no further Zika virus specific amino acid sequences are present in the polypeptide. This polypeptide does not immunologically cross-react with antibodies raised against structurally related antigens from tick-borne encephalitis virus, Dengue virus 1-4, West Nile virus, yellow fever virus or Japanese encephalitis virus, but immunologically reacts with antibodies raised against full length Zika virus NS1 antigen. Also disclosed is a method of producing a soluble and immunoreactive Zika virus NS1 polypeptide as well as methods and kits for detecting antibodies specific for Zika virus in an isolated sample.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.